In addition, a Phase I clinical trial showed that the combination therapy of Erlotinib and PI3K inhibitor (BKM120) was well tolerated in advanced NSCLC patients with EGFR-sensitizing mutations and acquired resistance [110]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.